Lightnews — Scholar-powered news

Reposted by Ryan Potts - real

Science Magazine @science.org · Aug 22

A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.”

Learn more: https://scim.ag/4lC2aCM

LOCKTACs comprise a subset of proximity drugs that stabilize naturally existing complexes. (A) Categories of proximity-based drugs. (B) Mechanism of PROTAC drugs. (C) LOCKTAC acting within a protein-protein interface. (D) LOCKTAC acting adjacent to a protein-protein interface. (E) Heterobifunctional LOCKTAC that does not bind at protein-protein interface. (F) Allosteric drugs induce conformational changes at a distance and are not LOCKTACs.

13 52

Ryan Potts - real @pottslab.bsky.social · Aug 22

Check out how the Amgen Induced Proximity team repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @dnalawansha0509.bsky.social and team! #mycompany www.nature.com/articles/s41...

LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation

Nature Communications - LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation,...

www.nature.com

1 15

Ryan Potts - real @pottslab.bsky.social · Aug 22

www.science.org/doi/10.1126/...

Load and lock: An emerging class of therapeutics that influence macromolecular dissociation

Biology is governed by macromolecular interactions, perturbation of which often lies at the heart of disease. Most therapeutic drugs, whether they are small molecules or biologics, exert their effects...

www.science.org

2 3

Ryan Potts - real @pottslab.bsky.social · Aug 22

What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology.
science.org/doi/10.1126/sc…shorturl.at/976aj#mycompnayay

https://science.org/doi/10.1126/sc…

2 3 9

Ryan Potts - real @pottslab.bsky.social · Jun 14

🎓 Recent STEM grad? Jump-start your PhD journey with Amgen’s new 2-yr paid Postbaccalaureate Research Fellowship in Thousand Oaks! Work with world-class scientists, publish your findings, and make a real impact for patients.
Apply by July 15 ➡️ amgen.wd1.myworkdayjobs.com/Careers/job/...

Postbaccalaureate Fellow - Research

Career Category Research Job Description Join Amgen’s Mission of Serving Patients At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients...

amgen.wd1.myworkdayjobs.com

1 3

Reposted by Ryan Potts - real

Dan Nomura @dannomura.bsky.social · Jun 10

Our latest paper w/ @pottslab.bsky.social & @amgen.bsky.social in @jacs.acspublications.org by co-first authors @cmzammit.bsky.social & Cory Nadel on discovery of covalent destabilizing degrader of AR & AR-V7 in prostate cancer. Thanks also to @themarkfdn.bsky.social ! pubs.acs.org/doi/10.1021/...

5 18

Ryan Potts - real @pottslab.bsky.social · Jun 3

Fabulous! Unfortunately, I’ll have to be there in spirit 👕 this year! Hoping to join at the next world tour 🚌 stop.

3

Reposted by Ryan Potts - real

Carolyn Bertozzi @carolynbertozzi.bskyverified.social · Apr 11

SCAM ALERT. This is a fake conference that ripped off my and other people’s names to trick people into registering. There is no such conference that I or the others shown were invited or agreed to. We are working to try to get this fraud taken down from the web.

chemsymposia.com

Join Chemsymposia 2026: Research & Innovation | ChemSymposia 2026

Join us at Chemsymposia 2026 to discover groundbreaking research in physics applications. Connect with experts, engage in insightful discussions, and explore our venue, registration details, and speak...

chemsymposia.com

8 110 200

Reposted by Ryan Potts - real

Carolyn Bertozzi @carolynbertozzi.bskyverified.social · Mar 28

Now we’re finally talking!

www.politico.com/news/2025/03...

www.politico.com

16 47 180

Reposted by Ryan Potts - real

Cell Chemical Biology @cp-cellchembiol.bsky.social · Mar 21

.@pottslab.bsky.social @amgen.bsky.social demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3 ubiquitin ligases with VIPER-TACs. http://dlvr.it/TJgF0r

1 2

Ryan Potts - real @pottslab.bsky.social · Mar 21

We anticipate that unbiased phenotypic screening in combination with biased E3-focused small molecule libraries will continue to be a fruitful approach to molecular glue discovery. This amazing work comes from a large team at @amgen.bsky.social in collaboration w/ @PlexiumTx. Congrats to all

Ryan Potts - real @pottslab.bsky.social · Mar 21

SAR analysis provided the opportunity to directly test the impact of altering k-on and k-off rates, which revealed that slow k-off as far more important than fast k-on for degradation activity. 7/8

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

Comprehensive mutational analysis revealed the GEMIN3 degron by which dGEM3 mediates recognition by VHL. 6/8

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

We extensively characterize the properties of dGEM3 to show biochemical reconstitution of the VHL:dGEM3:GEMIN3 ternary complex and ubiquitination consistent with a molecular glue without pre-existing affinity between VHL and GEMIN3. 5/7

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

Proteomics analysis reveals dGEM3 is a highly selective degrader and the direct target is the SMN complex protein GEMIN3. 4/8

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

We discover dGEM3 as a VHL-based molecular glue causing significant gene expression changes. 3/8

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

We use an innovative gene expression read out approach to do target-agnostic screening of a focused 26,000 VHL ligand library for molecular glue degraders. 2/8

1

Ryan Potts - real @pottslab.bsky.social · Mar 21

🚨 Rational discovery of VHL molecular glues. New Preprint from @amgen.bsky.social Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/8 www.biorxiv.org/content/10.1...

Discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq

Targeted protein degradation (TPD) is an emerging therapeutic modality in which small molecules are used to recruit targets to the natural protein degradation machinery of the cell. Molecular glue deg...

www.biorxiv.org

1 6 31

Ryan Potts - real @pottslab.bsky.social · Mar 20

Check out this cover highlighting @amgen.bsky.social postdoc Kyle Mangano’s work on VIPER-TACs! 🐍

Cell Chemical Biology @cp-cellchembiol.bsky.social · Mar 20

The March issue of Cell Chemical Biology is out! Click here to read it: #condensates #ferroptosis #lipids #VIPER-TACs #PRDX #ergothioneine #proximity #syntheticbio http://dlvr.it/TJfCD8

1 12

Reposted by Ryan Potts - real

Sylvie Callegari @sylviecallegari.bsky.social · Mar 13

Thrilled to share the structure of dimerised human PINK1 docked to an endogenous translocase array on the mitochondrial surface, composed of two TOM complexes, bridged by a VDAC2 dimer! Published today in Science www.science.org/doi/10.1126/...

@wehi-research.bsky.social @komanderlab.bsky.social

9 57 170

Reposted by Ryan Potts - real

Sherry Pagoto, PhD @drsherrypagoto.bsky.social · Mar 12

New report shows that NIH grants fueled $95 billion in economic activity and 407,782 jobs in 2024.

That's not to mention the countless lives that biomedical research has saved.

Show me a better investment than that.
www.forbes.com/sites/michae...

NIH Grants Fueled $95 Billion In FY 2024 Economic Activity, Finds New Report

National Institutes of Health grants generated almost $95 billion in economic activity nationwide in FY 2024 according to a new report by United for Medical Research.

www.forbes.com

23 1.1K 2K

Reposted by Ryan Potts - real

Cell Chemical Biology @cp-cellchembiol.bsky.social · Mar 5

Online now! @pottslab.bsky.social @amgen.bsky.social demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3 ubiquitin ligases with VIPER-TACs. http://dlvr.it/TJLmvh

3 4

Ryan Potts - real @pottslab.bsky.social · Mar 5

🚨Hiring Alert🚨 Recruiting an accomplished leader to serve as Director and Head of Discovery #Proteomics at Amgen. Find out more and apply here: careers.amgen.com/en/job/south...

Director of Discovery Proteomics Jobs at Amgen in United States of America

Explore the details of a Director of Discovery Proteomics career in South San Francisco. Live. Win. Thrive. Search and apply for a rewarding new career at Amgen.

careers.amgen.com

2 1

Ryan Potts - real @pottslab.bsky.social · Feb 18

Thanks to all co-authors on this amazing Amgen-UCBerkeley Molecular Therapeutics Initiative collaboration, especially Charlotte Zammit, Cory Nadel, Ying Lin, and Sajjan Koirala. 7/7

2

Ryan Potts - real @pottslab.bsky.social · Feb 18

Overall, these results indicated that EN1441 is a pathfinding molecule that directly engages AR-v7 Cys125, leading to destabilization and aggregation and the subsequent inhibition of AR transcriptional activity and ultimately ubiquitin-mediated proteasomal degradation. 6/7

1